


1



2

3

Figure S1. The percentage of lung immune cells after infection MA01

4

(A) Flow cytometry analysis of the percentage of lung CD11c- and F4/80-positive cells after infection with PBS and MA01 for 5 days (n=5 mice per group). (B) Flow cytometry analysis of the percentage of CD40- and CD86- positive cells in lung CD11c+ dendritic cells infected with PBS and MA01 for 5 days. (C) Flow cytometry analysis of the percentage of CD40-, CD86-, and MHC-II-positive cells in lung F4/80 macrophages infected with PBS and MA01 for 5 days. Data are presented as mean \pm SD; p-values were calculated using the two-tailed Student's t-test. **p < 0.01, ***p < 0.001, compared with PBS. Experiments depicted in this figure have been reproduced two times.

10

11

12

13


14

15

16

17

18



19

20 **Figure S2. CD83-positive cells in spleen after *C. Perfringens-Neu* treatment**

21 Flow cytometry analysis of the percentage of CD83-positive cells in spleen CD11c+ dendritic, CD3+ T,
22 CD4+ T, CD8+ T, and B220+ B cells 6 h after *C. Perfringens-Neu* (1 $\mu\text{g/ml}$) stimulation. Data are presented
23 as mean \pm SD; p-values were calculated using the two-tailed Student's t-test. **p < 0.01, ***p < 0.001, N.S.
24 (not significant), compared with PBS. Experiments depicted in this figure have been reproduced two times.

25

26

27

28


29

30

31

32

33



35

36 **Figure S3. CD83 positive cells in lung after oseltamivir treatment**

37 Flow cytometry analysis of the percentage of CD83 positive cells in lung CD11c⁺ dendritic cells and F4/80⁺
 38 macrophages infected with PBS and MA01 (with or without treatment of oseltamivir phosphate) for 5 days
 39 (n=5 mice per group). Data are presented as mean ± SD; p-values were calculated using the two-tailed
 40 Student's t-test. *p < 0.05, **p < 0.01, compared with MA01. Experiments depicted in this figure have been
 41 reproduced two times.

42